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BACKGROUND: Little information is available on the causes of death among persons with classic Kaposi’s sarcoma (CKS).
METHODS: We conducted a population-based study in Italy to identify deceased persons with CKS and the underlying causes of
death among them, by reviewing multiple-causes-of-death records. Standardised mortality ratios (SMRs) and 95% confidence
intervals were calculated to compare the distribution of causes to that among the same-age general population of deceased persons.
The geographical distribution was also evaluated.
RESULTS: Of the 946 deaths among persons with CKS, 65.9% were attributable to non-neoplastic conditions and 21.9% to
malignancies. For 12.2%, no lethal pathology was identified and CKS was considered as the underlying cause. In 90% of these cases,
there was visceral/nodal involvement, therapy-related complications, or neoplastic cachexia. Among persons with CKS who died of
other causes, an excess for lymphoid malignancies emerged (SMR¼4.40) (chronic lymphocytic leukaemia (11.03), non-Hodgkin’s
lymphoma (4.22), Hodgkin’s lymphoma (11.80), and multiple myeloma (2.3)), balanced by a deficit for all solid cancers (0.56), with a
marked deficit for lung cancer (0.41). We found an excess for respiratory diseases (chronic obstructive pulmonary disease (1.86)) and
genitourinary diseases (chronic renal failure (6.47)). There was marked geographical heterogeneity in the distribution of deaths.
CONCLUSIONS: Though referring specifically to Italy, the results are informative for other countries and populations and all cases of CKS
in general.
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Classic (or ‘Mediterranean’) Kaposi’s sarcoma (CKS) occurs in elderly
persons of mainly Mediterranean origin and is a rare outcome of
infection with the human herpesvirus 8 (HHV8). Several studies have
found an association (either positive or negative) between CKS and
an additional primary cancer, both when CKS was the first primary
neoplasm (Franceschi et al,1 9 9 6 ;H j a l g r i met al,1 9 9 7 ;I s c o v i c het al,
1999a) and when it was the second primary neoplasm (Iscovich et al,
1999b; Hisada et al, 2001), or regardless of the temporal order of
diagnosis (Cannon et al, 2000). A few studies have also reported an
association (positive or negative)w i t hav a r i e t yo fn o n - n e o p l a s t i c
diseases (Goedert et al, 2002; Guttman-Yassky et al,2 0 0 6 ;A n d e r s o n
et al, 2008).
Classic Kaposi’s sarcoma is rarely considered to be an actual
cause of death (Brambilla et al, 1994; Franceschi et al, 1996; Hiatt
et al, 2008). However, little information is available on the causes
of death among persons with CKS. No population-based studies
have been conducted, and the available information derives from
the sparse data retrieved from case series (Brambilla et al, 1994;
Lospalluti et al, 1995; Franceschi et al, 1996; Hiatt et al, 2008).
Furthermore, whereas the 10th revision of the International
Classification of Diseases (ICD-10) has a specific code for Kaposi’s
sarcoma (KS), the ICD-9, which in many countries is still used,
does not.
The objectives of this study were to investigate cause-specific
mortality among deceased persons with CKS and to determine
whether the distribution of the underlying causes differs compared
with the general population of deceased persons. To this end, we
conducted a population-based study in Italy, which is one of
the countries with the highest incidence rates of CKS in the
Mediterranean basin and where HHV8 infection is endemic.
Specifically, we reviewed multiple-causes-of-death records, which
have never been used to study mortality among persons with CKS;
we also evaluated the distribution by geographical area.
MATERIALS AND METHODS
Data sources
We used two data sources: the multiple-causes-of-death records
and the National Mortality Database, both managed by Italy’s
National Census Bureau (ISTAT). The multiple-causes-of-death
records are individual anonymous electronic records, which
contain, in addition to the underlying cause (that is, the disease
or injury that initiated the chain of events leading directly to
death), all causes of death exactly as typewritten out in full by the
medical examiner on the death certificate, in particular: (i) ‘other
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scauses resulting in the underlying cause’, (ii) ‘other significant
conditions’ (that is, those contributing to death yet not part of the
chain of events leading directly to death), and (iii) the ‘immediate/
final cause of death’ (that is, the final disease, injury or
complication directly causing death) (Israel et al, 1986; Wall
et al, 2005). The only geographical information collected in this
database is the province of death. The National Mortality Database
contains only the underlying cause of death, which until 2003 was
coded using ICD-9 (KS codified as 173.9, ‘other malignant
neoplasm of skin site unspecified’). It also contains the province
of birth.
The analysis was conducted on data referring to the period from
1995 (that is, the year in which the multiple-causes-of-death
records became available) to 2002 (that is, the year of the most
recent available data). We excluded deaths in the provinces of
Trento and Bolzano (both of which have small populations)
because these provinces do not record the multiple causes written
out in full.
Identification of deceased persons with CKS
Using the multiple-causes-of-death records, we identified all
persons for whom the term ‘Kaposi’ was written as any of the
above-mentioned causes (n¼1967, out of a total of 4452169
records). To exclude AIDS-related KS deaths, we carried out the
following: (i) we eliminated the records with mention of HIV or
AIDS anyplace on the death certificate; (ii) we manually reviewed
the remaining individual records and excluded those with mention
of AIDS-indicator opportunistic infections (WHO, 1994) (steps
(i) and (ii) resulted in the elimination of 902 records); and (iii) we
excluded all records for persons o65 years of age (n¼89),
limiting the analysis to older persons, who have an extremely low
prevalence of HIV/AIDS (Dal Maso et al, 2005); in our records,
only 4.5% of the decedents with KS and mention of HIV/AIDS
were aged X65 years. To exclude transplant-associated KS, we
eliminated the records that mentioned transplants (n¼30; 10
with heart transplant, 7 kidney, and 13 liver). The remaining 946
records were considered as ‘deaths with CKS’ and were used for
this analysis.
Causes of death among persons with CKS and differences
compared with the general population
To identify the underlying cause of death of the 946 persons with
CKS, we reviewed the individual records in the multiple-causes-of-
death database. KS was recorded as the underlying cause on 486
(51.4%) death certificates. Of these, 275 (56.6%) had both KS and
one or more lethal pathologies written as the underlying cause (for
example, malignant tumours, circulatory system diseases, and
respiratory system diseases). In these cases, the lethal pathology
was considered as the underlying cause (as mentioned, CKS is
rarely considered an actual cause of death); if more than one lethal
pathology was written, we selected the most plausible cause based
on an internationally accepted hierarchy of causes of death in ICD-9,
which is used by ISTAT. In the remaining 211 (43.4%) of the 486
death certificates with KS as the underlying cause, KS was the only
underlying cause; in these cases, we reviewed the ‘other causes
resulting in the underlying cause’ to determine whether they
included one or more lethal pathologies; this was the case in 95
of the 211 certificates (again, if more than one pathology was
identified, the underlying cause was assigned based on the
above-mentioned hierarchy). For the remaining 116 of the 211
certificates, no lethal pathology was found and KS was considered
as the cause of death (death ‘due to’ or ‘caused by’ CKS). We then
assigned the ICD-9 code to the 830 underlying causes of deaths,
that is, excluding the 116 cases in which KS was the only identified
cause (herein referred to as ‘KS alone’), for which no specific
ICD-9 code exists.
To determine whether there were excesses or deficits for specific
underlying causes of death among these 830 deceased persons
with CKS, we compared the observed number of deaths with
the expected number of deaths, calculated on the basis of the
proportion of deaths due to that underlying cause among the
same-age general population of persons who died in the same
period (that is, given that the underlying cause is the only cause
that is codified, it is the only cause that can be compared with
the official statistics for the general population). The ratio of
observed-to-expected cases can be considered as standardised
mortality ratio (SMR)-like (herein referred to as ‘SMR’). The SMR
was calculated for major groups of pathologies (for example,
cardiovascular disease, respiratory disease) and for some specific
pathologies (for example, specific cancers). The 95% confidence
intervals (CIs) were calculated based on the Byar’s formula, which
provides accurate approximations when working with small
numbers (Breslow and Day, 1987).
Geographical distribution of deceased persons with CKS
For the geographical analysis, we calculated the SMR for the region
of death, which was available for all 946 persons (Italy is divided
into 20 regions, each of which is divided into provinces). Given
that the area of birth is an important determinant because HHV8 is
mostly acquired during childhood (Whitby et al, 2000; Cattani
et al, 2003), we also calculated the SMRs for the region of birth (not
recorded on the multiple-causes-of-death records), by linking the
multiple-causes-of-death records with the National Mortality
Database, using the individual anonymous six-digit identification
code adopted for both databases. However, as the region of birth
has been recorded in the National Mortality Database only since
1998, this linkage was only possible for 679 persons. Finally, for the
regions of birth for which a significant SMR was found, we also
calculated the SMRs by province of birth.
When calculating the SMRs for the region of death and region of
birth, the reference population was Italy’s entire general popula-
tion for the same period. When calculating the provincial SMRs,
the reference population was that of the single regions in the same
period.
RESULTS
A total of 946 deaths among persons with CKS in the Italian
population of persons X65 years of age (range 65–101 years) were
evaluated (619 in men and 327 in women). The distribution of age
groups (that is, 65–74, 75–84, 85–94, and X95 years) significantly
differed by gender (Mann–Whitney test), with a median age of
82 years for men and 85 years for women. Only 171 (18.1%)
persons were o75 years of age. When we carried out the analyses
separately for men and women, no significant differences were
found with respect to the results for the two genders combined.
Of the 946 deaths, 65.9% were attributable to non-neoplastic
conditions, 21.9% to malignancies, and 12.2% to KS (that is, deaths
for which no lethal pathology was identified). The SMRs and the
95% CI for the major groups of underlying causes of death are
shown in Table 1. Compared with the general population, our
study population had a marginal deficit for all cancers combined.
There was also a deficit for diseases of the nervous system. When
considering all cardiovascular diseases combined, a small deficit
was found. This included a significant deficit for cerebrovascular
disease (SMR: 0.52; 95% CI: 0.41–0.66) and ischaemic heart
disease (SMR: 0.69; 95% CI: 0.56–0.85) (data not shown in the
table), whereas there was a nearly two-fold excess for heart failure
(SMR: 1.88; 95% CI: 1.26–2.68) and a small excess (though not
significant) for hypertension (SMR: 1.22; 95% CI: 0.89–1.63).
There was an excess for both respiratory and genitourinary
diseases. The excess for respiratory diseases was mainly attributable
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sto chronic obstructive pulmonary disease (COPD) and allied
conditions (SMR: 1.86; 95% CI: 1.45–2.37) and bronchopneumo-
nia/pneumonia (SMR: 1.90; 95% CI: 1.28–2.74), whereas that for
genitourinary diseases was mainly attributable to chronic renal
failure (SMR: 6.47; 95% CI: 4.70–8.80) (data not shown in the
table). There was no association for digestive diseases combined,
whereas there was a non-significant deficit for cirrhosis (the
most common digestive disease in our study) (SMR: 0.75; 95% CI:
0.39–1.31). Of the other causes, there was a deficit for senile
dementia (SMR: 0.39; 95% CI: 0.18–0.74) and a slight deficit (though
not significant) for diabetes (SMR: 0.68; 95% CI: 0.42–1.02).
For 116 (12.2%) death certificates, there was no mention of
any lethal pathology; thus KS was considered as the cause of death
(‘KS alone’). Of these cases, KS was disseminated or had visceral
or nodal involvement (n¼46; 39.7%), or there was mention of
neoplastic cachexia (n¼39; 33.6%) or senile decay or marasmus
(n¼10; 8.6%). In the remaining 21 (18.1%) cases, various compli-
cations were reported, including multiple skin ulcerations/necrosis
(n¼3), toxicity to chemotherapy or radiotherapy (n¼2), lower-
limb amputations (n¼2), and anasarca (n¼2), among others.
A primary cancer in addition to KS was recorded on 207 (21.9%)
death certificates (144 men and 63 women) (Table 2). There was a
deficit for all solid cancers combined. When considering specific
sites, a deficit was found for lung, stomach and colon–rectum
cancer; an excess, though not significant, was found for brain and
prostate cancer.
For all malignant neoplasms of lymphatic and hematopoietic
tissue, there was a more than four-fold excess, which was due to
chronic lymphocytic leukaemia (CLL), Hodgkin’s lymphoma (HL),
non-Hodgkin’s lymphoma (NHL), and multiple myeloma in both
men and women.
Double primary cancers (that is, two cancers in addition
to CKS) were recorded on 17 certificates (8.2%; 13 men and
4 women); 9 were solid-tumour pairs, 5 were solid/haematopoietic-
tumour pairs (3 with CLL), and 3 were haematopoietic-tumour
pairs (NHL/leukaemia; CLL/erythroleukaemia; CLL/Richter’s
syndrome).
Regarding the distribution by region of death, a wide hetero-
geneity emerged. There was an approximately three-fold excess
for Sardinia, an approximately two-fold excess for Puglia and
Calabria (southern Italy), a 1.5-fold excess for Lombardy (northern
Table 1 Underlying causes of death among persons with classic Kaposi’s
sarcoma; Italy, 1995–2002
Cause of death ICD-9 Observed Expected SMR 95 CI%
All cancers 140–239 207 241.7 0.86 0.74–0.98
Nervous system diseases
a 320–359 8 22.0 0.36 0.16–0.72
Cardiovascular diseases
b 390–459 343 419.6 0.82 0.73–0.91
Respiratory diseases
c 460–519 128 67.6 1.89 1.58–2.25
Genitourinary diseases
d 580–630 43 14.3 3.0 2.18–4.05
Digestive diseases
e 520–579 29 41.1 0.71 0.47–1.01
Other causes
f —7 2— — —
Kaposi’s sarcoma alone
g — 116 — — —
Total 946
aIncludes Parkinson’s disease (3), encephalopathy (3), multiple sclerosis (1), and
myelopathy (not otherwise specified) (1).
bIncludes hypertensive disease (46),
ischaemic heart disease (93), heart failure (30), cerebrovascular disease (68), other
forms of heart disease (70), pulmonary embolism, (3) and other vascular diseases
(33).
cIncludes chronic obstructive pulmonary diseases/emphysema/asthma (68),
bronchopneumonia (29), pneumothorax (2), pulmonary fibrosis (3), and other (26, of
which 6 pulmonary oedema).
dIncludes chronic renal failure (41) and urinary tract
infection (2).
eIncludes cirrhosis (12), ulcer (4), chronic hepatitis (5), intestinal
occlusion (2), pancreatitis/biliary disease (3), ascites/peritonitis (2), and liver failure (1).
fIncludes infectious and parasitic diseases (3), diabetes (22), autoimmune diseases
(12) (for example, rheumatoid arthritis, polymyositis, systemic lupus erythematosus,
and Sjo ¨gren syndrome), dementia (9), anaemia (16), bone marrow aplasia (5), and
other (5).
gDeath certificates without other underlying causes of death except
Kaposi’s sarcoma.
Table 2 Additional cancers among persons with classic Kaposi’s sarcoma; Italy, 1995–2002
Cancer type or site ICD-9 Observed Expected SMR 95 CI%
All solid cancers 140–199, 210–239 125 223.04 0.56 0.47–0.67
Stomach 151 6 18.79 0.32 0.12–0.69
Colon and rectum 153–154 15 26.40 0.57 0.32–0.94
Liver 155 7 8.20 0.85 0.34–1.76
Lung 161–162 19 46.50 0.41 0.25–0.64
Female breast 174 9 14.27 0.63 0.29–1.19
Prostate 185 19 13.32 1.43 0.86–2.23
Central nervous system
a 191–192 7 3.10 2.29 0.90–4.65
Other sites
b —2 5 — — —
Secondary neoplasms
c —1 8 — — —
Lymphatic and haematopoietic diseases 200–208 82 18.65 4.40 3.50–5.50
Non-Hodgkin’s lymphoma
d 200, 202 28 6.63 4.22 2.81–6.13
Hodgkin’s lymphoma 201 5 0.42 11.80 4.03–29.2
Multiple myeloma 203 9 3.97 2.27 1.03–4.27
Acute leukaemia
e 204.0, 205.0 2 — — —
Chronic lymphocytic leukaemia
f 204.1 22 1.99 11.03 6.90–16.70
Chronic myeloproliferative disorders
g —4 — — —
Myelodysplastic syndromes — 7 — — —
Lymphoproliferative disorders
h —5 — — —
All cancers 140–239 207 241.7 0.86 0.74–0.98
aIncludes glioma (2), glioblastoma (1), astrocytoma (3), and cerebral neoplasia (not otherwise specified) (1).
bIncludes cancers of the oesophagus (2), pancreas (3), kidney (2),
bladder (1), vulva/vagina (2), pleura (2), melanoma skin (1), non-melanoma skin (1), penis (2), gastrointestinal tract not otherwise specified (4), larynx (1), and uterus (4: 2 cervix
and 2 endometrium).
cIncludes liver, adrenal glands, lung, and brain metastasis of unknown primary sites.
dIncludes cerebral lymphoma (1, age 75), primary effusion lymphoma
(1, age 91), cutaneous lymphoma (1), and lymphoma (not otherwise specified) (2).
eIncludes myeloid (1) and leukaemia (not otherwise specified) (1).
fIncludes chronic
lymphocytic leukaemia (21) and hairy cell leukaemia (1).
gIncludes chronic myelogenous leukaemia (1), polycythemia vera (1), essential thrombocythemia (1), and chronic
idiopathic myelofibrosis (1).
hIncludes Waldenstro ¨m’s macroglobulinemia (1), Castleman’s disease (1), gammopathy (not otherwise specified) (1), and lymphoproliferative
diseases (not otherwise specified) (2).
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sItaly), and a non-significant excess (1.6-fold) for Basilicata
(southern Italy).
The distribution of deaths by region of birth (available for 679
persons) (Table 3) was similar to that by region of death, with a
more than two-fold excess for Sardinia, Calabria, and Puglia, and
a 1.3-fold excess for Lombardy. Basilicata (2.4-fold) and Sicily
(1.3-fold) also showed a significant excess, and Campania
(southern Italy) had a slight non-significant excess.
The analysis of SMRs by province of birth (data not shown in
the table) revealed excesses for two provinces in Lombardy, in
particular, Cremona (SMR: 4.33; 95% CI: 2.80–6.49) and Lodi
(SMR: 5.98; 95% CI: 3.53–9.72); the Taranto province in Puglia
(SMR: 1.69; 95% CI: 1.12–2.47); and the Matera province in
Basilicata (SMR: 2.06; 95% CI: 1.03–3.71). In Sardinia, two
provinces showed non-significant excesses, Sassari (SMR: 1.52;
95% CI: 0.91–2.37) and Oristano (SMR: 1.20; 95% CI: 0.44–2.61).
A deficit was found for two provinces in Lombardy, that is, Varese
(SMR: 0.42; 95% CI: 0.14–0.98) and Milano (SMR: 0.63; 95% CI:
0.43–0.88), and for the province of Catanzaro in Calabria (SMR:
0.28; 95% CI: 0.01–0.82).
DISCUSSION
The main findings of our study were that the leading underlying
causes of death among deceased elderly persons with CKS were
non-neoplastic conditions (65.9%), malignancies (21.9%), and ‘KS
alone’ (12.2%) (that is, deaths for which CKS was assigned as the
underlying cause). For non-neoplastic conditions, we observed
an excess for respiratory and genitourinary diseases. Regarding
malignancies, though there was an excess for all lymphoid malig-
nancies combined, which is consistent with most previous studies
(Iscovich et al, 1999a,b; Cannon et al, 2000), it was balanced by a
deficit for all solid cancers, also previously reported (Franceschi
et al, 1996; Hjalgrim et al, 1997; Iscovich et al, 1999a,b).
Regarding lymphoid malignancies, the 11-fold excess for CLL
confirms the significantly increased risk of KS among persons with
CLL (Iscovich et al, 1999b; Hisada et al, 2001). The four-fold excess
for NHL is also consistent with previous studies (Iscovich et al,
1999a,b; Cannon et al, 2000). Although no information was
available on the site or type of NHL, one death for primary effusion
lymphoma is of interest, given the rarity of this HHV8-associated
neoplasm among HIV-negative persons (Ascoli et al, 2002). With
respect to the nearly 12-fold excess for HL and the 2.2-fold excess
for myeloma (borderline significance), again, our findings confirm
previous reports (Iscovich et al, 1999b; Cannon et al, 2000;
Serraino et al, 2007).
Regarding solid cancers, the deficit for lung cancer, also
reported in other studies (Dictor and Attewell, 1988; Biggar et al,
1994; Hjalgrim et al, 1997; Iscovich et al, 1999a,b; Goedert et al,
2002), could be explained by the inverse association between
cigarette smoking and CKS (Anderson et al, 2008). However, our
results are only in part consistent with this association, in which
certain causes of smoking-attributable deaths showed a deficit
(smoking-associated vascular mortality: ischaemic heart disease
and cerebrovascular disease), whereas others showed an excess
(smoking-related respiratory mortality: COPD and allied condi-
tions). In any case, the literature on the association between CKS
and cardiovascular and respiratory diseases is conflicting (Goedert
et al, 2002; Guttman-Yassky et al, 2006; Anderson et al, 2008).
Of interest is the finding that 17 (8.2%) of the 207 persons with
malignancies as the cause of death had double primary cancer.
Although this number is small, ours is the first study to measure
the occurrence of two independent primary cancers in separate
organs in persons with CKS (previous studies were case reports)
(Cottoni et al, 2002).
Although direct comparisons are difficult, the pattern of
excesses/deficits for cancers in our study showed both similarities
and differences when compared with persons with HIV/AIDS and
transplant recipients (Grulich et al, 2007; Serraino et al, 2007; Dal
Maso et al, 2009). In particular, we found a deficit for all cancers
combined, compared with an excess reported for the other
populations; lymphoid malignancies showed an excess in both
our population and the others. Our deficit for lung cancer is in
contrast to the excess for the other populations. The similarities
for lymphoid malignancies could reflect immunological perturba-
tions (immunodepression in persons with HIV/AIDS and trans-
plant recipients and immunesenescence/inflammaging (Ostan
et al, 2008) in elderly persons with CKS), whereas the differences
for solid cancers could reflect different lifestyles/risk factors.
With regard to non-neoplastic diseases, the six-fold excess for
chronic renal failure is consistent with the more than four-fold
excess for kidney failure/dialysis in persons with CKS (Anderson
et al, 2008), which, however, remains unexplained. Persons with
chronic renal failure are at risk of developing HHV8-related
diseases, and KS is a rare complication of glomerular diseases
(Agbaht et al, 2007).
Concerning the considerable proportion of deaths (12.2%) that
we assumed were actually caused by CKS, on 490% of these death
certificates there were indications of the most aggressive forms of
CKS (Brambilla et al, 2003), in particular, visceral/nodal involve-
ment, complications related to therapy, or neoplastic cachexia (the
remaining 10% were persons with senile decay). For the other
persons with CKS yet who died of other causes, there was no
indication of the specific stage of CKS, which is not recorded on
death certificates. However, we can assume that CKS was not
advanced, given that there was no mention of advanced disease
anywhere on the death certificate. With regard to the length of
survival, though this information is not available on death
certificates, if we compare the median age at diagnosis in Italy
(Dal Maso et al, 2005) to the median age at death in our study, we
Table 3 Mortality by region of birth among persons with classic Kaposi’s
sarcoma; Italy, 1998–2002
Region
No. of
deaths
Crude
rates Expected SMR 95% CI
Northern
Piedmont 16 0.36 57.2 0.28 (0.16–0.45)
Valle d’Aosta 1 0.88 1.5 0.68 (0.01–3.7)
Liguria 12 0.60 26.1 0.46 (0.24–0.80)
Lombardy 132 1.65 103.9 1.27 (1.06–1.50)
Trentino-Alto Adige 3 0.38 10.2 0.29 (0.06–0.86)
Veneto 23 0.57 52.5 0.44 (0.28–0.66)
Friuli-Venezia Giulia 3 0.24 16.3 0.18 (0.04–1.35)
Emilia-Romagna 60 1.36 57.2 1.05 (0.80–1.35)
Central
Marche 11 0.70 20.4 0.54 (0.27–0.96)
Tuscany 16 0.41 50.5 0.32 (0.18–0.51)
Umbria 4 0.43 12.1 0.33 (0.09–0.85)
Latium 14 0.31 58.8 0.24 (0.13–0.40)
Southern
Campania 61 1.54 51.6 1.18 (0.90–1.52)
Abruzzi 13 1.02 16.5 0.79 (0.42–1.35)
Molise 3 0.89 4.4 0.68 (0.14–1.99)
Puglia 115 3.69 40.5 2.84 (2.34–3.41)
Basilicata 17 3.14 7.0 2.41 (1.4–3.89)
Calabria 58 3.44 21.9 2.65 (2.01–3.42)
Insular
Sicily 72 1.74 53.7 1.34 (1.05–1.69)
Sardinia 45 3.53 16.6 2.72 (1.98–3.63)
Italy 679 1.30 679.0 1.00
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scan roughly calculate that survival is B10 years, which is
consistent with previous studies (Brambilla et al, 1994; Franceschi
et al, 1996).
The geographical analysis showed a wide heterogeneity, though
the reasons for the findings are unknown. In particular, our results
confirmed that being born in southern Italy or the Islands is a risk
factor for CKS (Geddes et al, 1995; Dal Maso et al, 2005), and we
identified the specific regions in these areas. The results also
revealed an excess for persons born in two adjacent provinces in
the northern region of Lombardy, which is consistent with the
increased incidence of CKS and high HHV8 seroprevalence in
another adjacent province (Ascoli et al, 2001; Tanzi et al, 2005).
These provinces are located in the Po Valley, which, together
with Sardinia, Sicily, and Puglia, has shown evidence of a higher
incidence of CKS and seroprevalence of HHV8, compared with
other areas in Italy (Lospalluti et al, 1995; Calabro et al, 1998;
Whitby et al, 2000; Cattani et al, 2003). This could be related to
environmental risks, including having been born in areas with
endemic malaria (Geddes et al, 1995) and exposure to blood-
sucking insects (Coluzzi et al, 2002; Ascoli et al, 2006).
In drawing conclusions, some potential limits need to be
mentioned. We excluded the 89 persons o65 years of age, some
of whom may have been non-AIDS KS. Conversely, we may
have included cases of iatrogenic (non-transplant) KS (that is, the
12 deaths for which the underlying cause was an autoimmune
disease), though the relationship between CKS and iatrogenic KS is
ambiguous and perhaps artificial. Regarding ascertainment bias,
we are reasonably sure that there were no false positives, simply
because of the peculiarity of the term ‘Kaposi’ and considering that
in Italy KS has been diagnosed and reported as a cause of death for
a number of decades using procedures that are homogeneous
throughout the country. However, we cannot exclude the possi-
bility of false negatives, a limitation that is inherent to death
certificates (Redelings et al, 2007). Moreover, in comparing the two
data sources, in the National Mortality Database some pathologies
may be underestimated or overestimated, which would have an
effect on our results. For certificates with both KS and another
pathology as the underlying cause, we defined the lethal pathology
as the cause, so that we may have underestimated the number of
deaths for CKS alone and/or overestimated the number of deaths
for other causes. Furthermore, some of the persons for whom the
region of birth was not available may have been born outside Italy
and acquired HHV8 infection abroad. However, this is extremely
unlikely, given the advanced age of our population and that mass
immigration in Italy is a very recent phenomenon. Finally, though
not a limit of the study, it should be stressed that we used mortality
data and that consequently not all persons with KS were identified.
Nonetheless, it was not our objective to use mortality data as an
indicator of prevalence.
To the best of our knowledge, this is the first population-
based investigation of cause-specific mortality among deceased
persons with CKS, which included a large number of cases (total of
946). Moreover, the results, which cover an extensive period,
refer to Italy’s entire population (about 57 million); previous
population-based studies on CKS in Italy were based on incidence
data provided by a network of cancer registries, which does
not cover the entire country (Dal Maso et al, 2005). Though
referring specifically to Italy, the results are also informative
for other countries and populations and all cases of CKS in
general.
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